Surface Oncology, a clinical-stage biotech developing next generation antibody cancer therapies, filed on Friday with the SEC to raise up to $75 million in an initial public offering.
The Cambridge, MA-based company was founded in 2014 and booked $13 million in sales for the 12 months ended December 31, 2017. It plans to list on the Nasdaq under the symbol SURF. Surface Oncology filed confidentially on November 17, 2017. Goldman Sachs, Cowen & Company and Evercore ISI are the joint bookrunners on the deal. No pricing terms were disclosed.
